Subcutaneous injection or oral use
Sermorelin
Growth hormone-releasing hormone analog
FDA status
In FDA's 503B Category 1: interim enforcement discretion, not the bulks list.
$229 per month
*If medically eligible.The collection
Explore peptide care.
Your options, clearly explained. Explore the collection by format, compare pricing, and find the details that matter to you.
23 products
Product collection- Order now
Subcutaneous injection
Glutathione
Antioxidant tripeptide
FDA status
In FDA's Category 1 for 503A pharmacies and 503B outsourcing facilities: interim enforcement discretion, not the bulks list.
Order now$229 per month
*If medically eligible.Subcutaneous injection
Methylcobalamin B12
Vitamin B12, methyl form
FDA status
In FDA's Category 1 for 503A pharmacies and 503B outsourcing facilities: interim enforcement discretion, not the bulks list.
Order now$229 per month
*If medically eligible.Subcutaneous injection
CJC-1295 and Ipamorelin
Growth hormone secretagogue combination
FDA status
No compounding pathway today.
The CJC-1295 and Ipamorelin combination is not FDA-approved, and there is no lawful pathway for a US pharmacy to compound it today. Its safety and effectiveness in people have not been established.
Order now$229 per month
*If medically eligible.Subcutaneous injection
MOTS-c
Mitochondrial-derived peptide
FDA status
No compounding pathway today. An FDA advisory committee recommendation is not a listing.
MOTS-c is not FDA-approved, and there is no lawful pathway for a US pharmacy to compound it today. Its safety and effectiveness in people have not been established.
Order now$229 per month
*If medically eligible.Subcutaneous injection
BPC-157 Injection
Synthetic 15-amino-acid peptide
FDA status
No compounding pathway today. An FDA advisory committee recommendation is not a listing.
BPC-157 Injection is not FDA-approved, and there is no lawful pathway for a US pharmacy to compound it today. Its safety and effectiveness in people have not been established.
Order now$229 per month
*If medically eligible.Subcutaneous injection
Epitalon
Synthetic tetrapeptide
FDA status
No compounding pathway today. An FDA advisory committee recommendation is not a listing.
Epitalon is not FDA-approved, and there is no lawful pathway for a US pharmacy to compound it today. Its safety and effectiveness in people have not been established.
Order now$229 per month
*If medically eligible.Nasal spray or subcutaneous injection
Semax
Synthetic ACTH-fragment peptide
FDA status
No compounding pathway today. An FDA advisory committee recommendation is not a listing.
Semax is not FDA-approved, and there is no lawful pathway for a US pharmacy to compound it today. Its safety and effectiveness in people have not been established.
Order now$229 per month
*If medically eligible.Nasal spray or subcutaneous injection
Selank
Tuftsin-derived synthetic peptide
FDA status
No compounding pathway today.
Selank is not FDA-approved, and there is no lawful pathway for a US pharmacy to compound it today. Its safety and effectiveness in people have not been established.
Order now$229 per month
*If medically eligible.Subcutaneous injection
AOD-9604
Modified growth hormone fragment
FDA status
No compounding pathway today.
AOD-9604 is not FDA-approved, and there is no lawful pathway for a US pharmacy to compound it today. Its safety and effectiveness in people have not been established.
Order now$229 per month
*If medically eligible.Subcutaneous injection
GHK-Cu Injection
Copper-binding tripeptide for injection
FDA status
No compounding pathway today.
GHK-Cu Injection is not FDA-approved, and there is no lawful pathway for a US pharmacy to compound it today. Its safety and effectiveness in people have not been established.
Order now$229 per month
*If medically eligible.Oral use
BPC-157 Capsules
BPC-157 in an oral capsule format
FDA status
No compounding pathway today. An FDA advisory committee recommendation is not a listing.
BPC-157 Capsules is not FDA-approved, and there is no lawful pathway for a US pharmacy to compound it today. Its safety and effectiveness in people have not been established.
Order now$229 per month
*If medically eligible.Topical application
Topical GHK-Cu
Copper-binding tripeptide for topical use
FDA status
In FDA's 503A Category 1: interim enforcement discretion, not the bulks list.
Order now$229 per month
*If medically eligible.Subcutaneous injection
Wolverine Stack
BPC-157 + TB-500 fragment blend
FDA status
No compounding pathway today. An FDA advisory committee recommendation is not a listing.
The Wolverine Stack combination is not FDA-approved, and there is no lawful pathway for a US pharmacy to compound it today. Its safety and effectiveness in people have not been established.
Order now$229 per month
*If medically eligible.Subcutaneous injection
GLOW Stack
GHK-Cu + BPC-157 + TB-500 fragment blend
FDA status
No compounding pathway today.
The GLOW Stack combination is not FDA-approved, and there is no lawful pathway for a US pharmacy to compound it today. Its safety and effectiveness in people have not been established.
Order now$229 per month
*If medically eligible.Subcutaneous injection
KLOW Stack
GHK-Cu + BPC-157 + KPV + TB-500 fragment blend
FDA status
No compounding pathway today.
The KLOW Stack combination is not FDA-approved, and there is no lawful pathway for a US pharmacy to compound it today. Its safety and effectiveness in people have not been established.
Order now$229 per month
*If medically eligible.Subcutaneous injection
Semax / Selank Injection
Semax + selank blend
FDA status
No compounding pathway today.
The Semax / Selank Injection combination is not FDA-approved, and there is no lawful pathway for a US pharmacy to compound it today. Its safety and effectiveness in people have not been established.
Order now$229 per month
*If medically eligible.Subcutaneous injection
Kisspeptin Injection
Kisspeptin-10 peptide
FDA status
No compounding pathway today.
Kisspeptin Injection is not FDA-approved, and there is no lawful pathway for a US pharmacy to compound it today. Its safety and effectiveness in people have not been established.
Order now$229 per month
*If medically eligible.Subcutaneous injection
DSIP Injection
Emideltide, also called DSIP
FDA status
No compounding pathway today.
DSIP Injection is not FDA-approved, and there is no lawful pathway for a US pharmacy to compound it today. Its safety and effectiveness in people have not been established.
Order now$229 per month
*If medically eligible.Subcutaneous injection
Tesamorelin
Compounded tesamorelin does not lawfully exist: tesamorelin is regulated as a biological product, and compounding pharmacies have no pathway to make it.
FDA status
Cannot be compounded.
View detailsInformational listing
Subcutaneous injection
Tesamorelin / Ipamorelin Injection
A combination of tesamorelin and ipamorelin. This informational listing describes the ingredients and their regulatory records; it is not offered for ordering.
FDA status
Cannot be compounded.
View detailsInformational listing
Prescription products require an online evaluation with a licensed provider. Not all patients qualify.
Know your options
A clearer picture.
Before you choose.
Our FDA status tracker covers 24 substances, including peptides outside this collection. Each record links to its sources.
Before you begin
Intake has not opened yet. Each product page shows its launch status.
A licensed provider decides whether any product is appropriate for you, and may decline. Each product profile covers the evidence, risks and regulatory status.
Removal from FDA's Category 2 is not FDA approval and not a listing. FDA removed several peptides from its 503A Category 2 after their nominators withdrew the nominations, not because the substances were found safe: BPC-157, TB-500, MOTS-c, semax and epitalon among others (removal noticed April 15, 2026, effective after 7 days), and CJC-1295 and ipamorelin earlier (removal notice dated September 27, 2024). None was added to the 503A bulks list, so none has a compounding pathway today. A favorable vote by FDA's Pharmacy Compounding Advisory Committee is a recommendation, not a listing: nothing changes unless FDA publishes a final rule.
An FDA advisory committee recommendation is not a listing. Nothing changes unless FDA publishes a final rule.